Back to News
Market Impact: 0.12
Avalyn Pharma Adds Former FDA Executive To Board As AP01, AP02 Trials Progress
Source: Nasdaq
Healthcare & BiotechManagement & Governance
Avalyn Pharma appointed Robert J. Meyer, a pulmonary physician and former senior FDA executive, to its board of directors. The addition may strengthen regulatory and clinical expertise for the clinical-stage biopharmaceutical company, but no financial, trial, or product-development updates were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
AVLN0.30
More News
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- NUBURU Completes Tekne Acquisition, Adding a $93 Million Defense & Dual-Use Program Portfolio and Advancing Expansion Across NATO and Allied Markets
- BTIG cuts Acumen Pharmaceuticals stock price target to $1 on trial results
- Jefferies raises West Pharmaceutical stock price target on HVP growth
- Microsoft's moolah mountain is more massive than ever. It just doesn't want the people who built it
- Berkshire earnings on deck: Abel’s railroad bets under scrutiny Monday